Advertisement
U.S. markets open in 2 hours 56 minutes

Supernus Pharmaceuticals, Inc. (SUPN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
34.19+1.21 (+3.67%)
At close: 04:00PM EDT
34.19 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close32.98
Open33.15
Bid24.07 x 1100
Ask33.00 x 800
Day's Range32.54 - 34.30
52 Week Range21.99 - 39.09
Volume422,542
Avg. Volume363,685
Market Cap1.871B
Beta (5Y Monthly)0.97
PE Ratio (TTM)1,709.50
EPS (TTM)0.02
Earnings DateMay 07, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est40.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-43% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for SUPN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Supernus Pharmaceuticals, Inc.
    SUPN: Raising target price to $26.00SUPERNUS PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $26.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    Supernus to Participate in Two Upcoming Investor Conferences

    ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences: Jefferies Biotech on the Bay SummitDate:Tuesday, March 12, 2024Place:The 1 Hotel South Beach, Miami, Fla. Barclays Glob

  • Insider Monkey

    11 Best Small Cap Pharma Stocks to Invest In

    In this piece, we will take a look at the 11 best small cap pharma stocks to invest in. If you want to skip our overview of the global pharmaceutical and healthcare industry, which is one the most unique sectors in the world, then you can check out 5 Best Small Cap Pharma Stocks to […]

  • Simply Wall St.

    Supernus Pharmaceuticals Full Year 2023 Earnings: Beats Expectations

    Supernus Pharmaceuticals ( NASDAQ:SUPN ) Full Year 2023 Results Key Financial Results Revenue: US$607.5m (down 8.9...